Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About

In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18 days. Repurposing drugs designed to treat other diseases to now treat COVID-19 is one of the quickest ways to find a new therapy to control the current pandemic. Also in April, researchers at Vanderbilt University enrolled the first patients in a much-anticipated study of hydroxychloroquine. It’s already approved to treat malaria and certain autoimmune disorders like rheumatoid arthritis and lupus but hasn’t been studied, until now, against coronavirus. Yet the medication has become a sought-after COVID-19 treatment after first Chinese doctors, and then President Trump touted its potential in treating COVID-19. The data from China is promising but not conclusive, and infectious disease experts, including Trump’s coronavirus task force scientific advisor Dr. Anthony Fauci, aren’t convinced it’s ready for prime time yet in Ameri...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news

Related Links:

More News: Academia | AIDS Vaccine | Allergy | Allergy & Immunology | American Health | Arthritis | Autoimmune Disease | Babies | Babies Heart Conditions | Back Pain | Biotechnology | Botulism | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Chemistry | China Health | Clinical Trials | Common Cold | Congo Health | Coronavirus | Cough | COVID-19 | Databases & Libraries | Dengue Fever | Disability | Ebola | Ebola Vaccine | Emergency Medicine | Epidemics | Epidemiology | Epilepsy | Erectile Dysfunction | Flu Pandemic | Food and Drug Administration (FDA) | Funding | Gabapentin | Genetics | Health | Health Management | Heart | Heart Disease | Heart Transplant | HIV AIDS | Hospitals | Hydroxychloroquine | Infectious Diseases | Influenza | Influenza Vaccine | Intensive Care | International Medicine & Public Health | Investigational New Drugs | Japan Health | Learning | Lung Transplant | Lupus | Malaria | Malaria Vaccine | Measles | Measles Vaccine | MERS | Microbiology | Mumps | Mumps Vaccine | National Institutes of Health (NIH) | Neurontin | Nurses | Nursing | Outbreaks | Pain | Pandemics | Parasitic Diseases | Parasitology | Pneomococcal Vaccine | Pneumonia | Politics | Respiratory Medicine | Rheumatoid Arthritis | Rheumatology | SARS | Science | Skin | Solo Practices | Study | Switzerland Health | Texas University | Toxicology | Trump | Universities & Medical Training | University of Minnesota | USA Health | Vaccines | Veterinary Vaccinations | Viagra | Women